Codex Capital’s Edwards Lifesciences EW Stock Holding History

Codex Capital’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,000	Closed	-$206K	–	42
2021 Q2	$206K	Buy	+2,000	New	+$189K	0.11%	44

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Codex Capital's EW Position: Q3 2021 in Review

Codex Capital sold out of Edwards Lifesciences (EW) in Q3 2021, closing a stake of 2,000 shares — an estimated $206K sold.

Codex Capital first reported a position in EW in Q2 2021 and held it in 1 quarter. The position peaked at $206K in Q2 2021. 1,227 funds tracked by Wall St. Rank hold EW as of Q3 2021.

Codex Capital reported no remaining Edwards Lifesciences position as of Q3 2021 after selling out during the quarter.
Codex Capital sold 2,000 Edwards Lifesciences shares in Q3 2021, an estimated $206K.
Codex Capital first reported a position in Edwards Lifesciences in Q2 2021 and held it in 1 quarter.
Codex Capital's Edwards Lifesciences position peaked at $206K in Q2 2021.
1,227 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2021.

Based on Codex Capital's 13F filing for Q3 2021, filed 15 Nov 2021.